New approaches for risk assessment of patients with myelodysplastic syndrome

被引：0
|
作者：
Micheva, I. [1 ]
Gerov, V. [1 ]
Rachev, R. [1 ]
Varbanov, H. [1 ]
Efraim, M. [1 ]
Stavrev, N. [1 ]
Angelova, L. [1 ]
Gercheva, L. [1 ]
机构：
[1] Univ Hosp, Hematol, Varna, Bulgaria
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70186-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-138
引用
收藏
页码：S85 / S86
页数：2
相关论文
共 50 条
  • [31] ANALYSIS OF EXPANSION MESENCHYMAL STROMAL IN PATIENTS WITH LOW RISK MYELODYSPLASTIC SYNDROME
    Duarte, F.
    Lemes, R.
    Vasconcelos, J.
    Rocha, F.
    Zalcberg, I.
    Coutinho, D.
    Silla, L.
    Valim, V.
    Barbosa, M.
    Santos, T.
    Goncalves, R.
    Carlos, L.
    Vasconcelos, P.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S91 - S92
  • [32] Experience with the use of azacitidine in patients with low-risk myelodysplastic syndrome
    Duarte, F.
    Santos, T.
    Barbosa, M.
    Santos, T.
    Goncalves, R.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S166 - S166
  • [33] Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi, Farhad
    Borthakur, Gautam
    Cortes, Jorge
    O'Brien, Susan
    Gandhi, Varsha
    Plunkett, William
    Byrd, Anna L.
    Kwari, Monica
    Kantarjian, Hagop
    [J]. BLOOD, 2009, 114 (22) : 53 - 54
  • [34] Cause of death in patients with lower-risk myelodysplastic syndrome (MDS)
    Conley, A. P.
    Stevenson, W.
    Pierce, S.
    Cortes, J. E.
    O'Brien, S. M.
    Ravandi, F.
    Kantarjian, H. M.
    Garcia-Manero, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] PROGNOSTIC SIGNIFICANCE OF COMORBIDITIES AND FRAILTY IN RISK STRATIFICATION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME
    Efraim, M.
    Micheva, I.
    [J]. LEUKEMIA RESEARCH, 2021, 108 : S41 - S41
  • [36] Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome
    Komrokji, Rami S.
    Corrales-Yepez, Maria
    Al Ali, Najla
    Kharfan-Dabaja, Mohammad
    Padron, Eric
    Fields, Teresa
    Lancet, Jeffrey E.
    List, Alan F.
    [J]. CANCER, 2012, 118 (10) : 2659 - 2664
  • [37] Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients
    Lee, Wan-Hsuan
    Lin, Chien-Chin
    Tsai, Cheng-Hong
    Tseng, Mei-Hsuan
    Kuo, Yuan-Yeh
    Liu, Ming-Chih
    Tang, Jih-Luh
    Sun, Hsun-, I
    Chuang, Yi-Kuang
    Chou, Wen-Chien
    Hou, Hsin-An
    Tien, Hwei-Fang
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (12) : 1589 - 1598
  • [38] The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome
    Falantes, Jose F.
    Marquez-Malaver, Francisco J.
    Knight, Teresa
    Calderon-Cabrera, Cristina
    Martino, Maria L.
    Gonzalez, Jose
    Montero, Isabel
    Espigado, Ildefonso
    Perez-Simon, Jose A.
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 (08) : 1893 - 1902
  • [39] Personalized risk model for predicting risk of acute coronary syndrome in patients with myelodysplastic syndromes
    Montarello, Natalie
    Leslie, Alasdair
    Chhetri, Rakchha
    Friel, Oisin
    Singhal, Deepak
    Ross, David
    Yeung, David
    Kok, Chung H.
    Psaltis, Peter J.
    Hiwase, Devendra K.
    [J]. BLOOD ADVANCES, 2023, 7 (13) : 3032 - 3035
  • [40] Survival Advantage with Hypomethylating Agents In Patients with Higher Risk Myelodysplastic Syndrome
    Park, Young-Hoon
    Lee, Je-Hwan
    Lee, Kyoo Hyung
    Lee, Jung-Hee
    Kim, Dae-Young
    Kim, Sung-Doo
    Lim, Sung-Nam
    Choi, Yunsuk
    Seol, Mice
    Lee, Young-Shin
    Kang, Young-A
    Jeon, Mijin
    [J]. BLOOD, 2010, 116 (21) : 775 - 775
12345